Sunday, January 15, 2017 9:36:06 PM
I want to see how much of a change immunopulse IL-12 can make in these exhausted phenotype percentages for CD8 TIL. We know that, based on interim phase 2 data, immunopulse IL-12 is able to convert 40% of predicted non-responders into responders (and some of these patients were actual non-responders to a variety of prior therapies including pembrolizumab). ARE THEY PRIMING THESE PATIENTS FOR PEMBROLIZUMAB BY ACTUALLY ELEVATING THEIR CTLA-4hi/PD-1hi CD8 TIL PHENOTYPE PERCENTAGES ABOVE 20%?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM